Article Text

PDF
Hu-antibody-positive patients with or without cancer have similar clinical profiles
  1. A Lladó1,
  2. A F Carpentier2,
  3. J Honnorat3,
  4. P Sillevis-Smitt4,
  5. A Twijnstra5,
  6. Y Blanco6,
  7. I K Hart7,
  8. A Saiz8,
  9. F Graus9
  1. 1Service of Neurology, Hospital Clínic, Barcelona, Spain; Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain
  2. 2Service of Neurology, Hôpital Salpêtrière, Paris, France
  3. 3Service of Neurology, Hopital Neurologique, Lyon, France
  4. 4Service of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands
  5. 5Service of Neurology, University Hospital Maastricht, Maastricht, The Netherlands
  6. 6Service of Neurology, Hospital Clínic, Barcelona, Spain; Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona
  7. 7Neuroimmunology Group, University Department of Neurological Science, Walton Center, Liverpool, UK
  8. 8Service of Neurology, Hospital Clínic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS)
  9. 9Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS)
  1. Correspondence to:
 Dr Francesc Graus
 Service of Neurology, Hospital Clínic, Villarroel 170, Barcelona 08036, Spain; fgraus{at}clinic.ub.es

Statistics from Altmetric.com

Hu-antibodies (Hu-abs) are markers of paraneoplastic neurological syndrome (PNS), almost always associated with small-cell lung carcinoma. A few patients with PNS who are Hu-ab positive, however, never develop cancer after long-term follow-up.1 If there were clinical differences, they could help identify those Hu-ab-positive patients who would not need serial screening for cancer. In this study, we analysed the clinical profile of Hu-ab-positive patients without cancer after a follow-up of more than 3 years and compared the findings with those in Hu-ab-positive patients with a tumour.

Methods

Of a total of 608 patients from our databases, we retrospectively identified 68 patients with PNS who were positive for Hu-abs, and had a follow-up of at least 3 years from the onset of the neurological syndrome. Patients were divided into two groups, according to the presence or absence of cancer during the follow-up. All patients without cancer underwent at least a CT of the chest. All of them had serial clinical and radiological (CT or chest x ray) examinations during the follow-up.

We analysed the following variables: age, sex, smoking habit, type of PNS, time to diagnosis of Hu-ab syndrome and Rankin score at diagnosis and at last visit. Data were analysed with SPSS V.10.0. The ethical committee of the hospital clinic approved …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.